Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Patent
1996-02-27
1997-07-29
Fay, Zohreh
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
514912, 514913, A61K 31535
Patent
active
056522363
ABSTRACT:
Pharmaceutical compositions and a method are disclosed for treating glaucoma and/or ocular hypertension in the mammalian eye by administering to the mammalian eye the pharmaceutical composition of the invention which contains as the active ingredient one or more compounds having guanylate cyclase inhibition activity. Examples of guanylate cyclase inhibitors utilized in the pharmaceutical composition and method of treatment are methylene blue, butylated hydroxyanisole and N-methylhydroxylamine.
REFERENCES:
patent: 4757089 (1988-07-01), Epstein
The Journal of Pharmacology and Experimental Therapeutics, vol. 247, No. 1, pp 283-288, 1988, Mulsch et al "LY 83583 Interferes with the Release of Endothelium-Derived Relaxing Factor and Inhibits Soluble Guanylate Cyclase".
The Journal of Pharmacology and Experimental Therapeutics, vol. 232, No. 3, pp 764-769, 1985, Schmidt et al, "LY83583: An Agent That Lowers Intracellular Levels of Cyclic Guanosine 3', 5'-Monophosphate.sup.1 ".
Eur. J. Biochem., Vol. 116:479-486, 1981, Gerzer et al, "Purification of a Soluble, Sodium-Nitroprusside-Stimulated Guanylate Cyclase From Bovine Lung".
Eur. J. Pharmacol, vol. 135, pp 247-250, 1987, Mulsch et al, "Stimulation of Soluble Guanylate Cyclase By Endothelium-Derived Relaxing Factor From Cultured Endothelial Cells".
Schultz, G. and E. Bohme, Guanylate cyclase. In: Methods of Enzymatic Analysis, 3, 379-389, 1984, Schultz et al, "GTP pyrophosphate-lyase (cyclizing), EC 4.6.1.2", ed. H.U. Bergmeyer, Verlag Chemie, Weinheim.
Allergan
Baran Robert J.
Fay Zohreh
Lambert Howard R.
Voet Martin A.
LandOfFree
Method for reducing intraocular pressure in the mammalian eye by does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for reducing intraocular pressure in the mammalian eye by, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for reducing intraocular pressure in the mammalian eye by will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-633914